Initial in vitro and in vivo studies have shown these CRAd-p53 vectors are a safe and effective therapy for inducing anti-tumor effects and have been shown to induce higher p53 expression and stronger anti-tumor effects than the Ad-53 vectors, highlighting their potential in future clinical trials. The gene discussed is TP53; the disease is neoplasm.